1-丙基吡咯烷-2,4-二酮 | 89159-03-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 1-丙基吡咯烷-2,4-二酮
• 英文名称: 1-propyl-2,4-dioxopyrrolidine
• 英文别名: 1-Propylpyrrolidine-2,4-dione
• CAS: 89159-03-5
• 化学式: C₇H₁₁NO₂
• 分子量: 141.17
• InChiKey: FOSJOOJRBLPLLS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  37.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-丙基吡咯烷-2,4-二酮 在 对甲苯磺酸 、 cadmium(II) chloride 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 生成 4-Amino-6,7-dihydro-1-pentyl-6-propylpyrazolo<3,4-b>pyrrolo<3,4-e>pyridin-5(1H)-one
  参考文献：
  名称：

  Synthesis of Tricyclic Aminopyridines by a Cadmium Promoted Cyclization

  摘要：

  A novel cyclocondensation of o-amino nitriles with cyclic 1,3-diones has been developed as a synthetic route to assemble fused tricyclic aminopyridine derivatives. The reaction sequence involves the initial formation of an enaminone. The enaminone is then cyclized at 120 degrees C to 190 degrees C in the presence of Lewis acids which include zinc, cadmium and copper(I) salts. The cyclization may be promoted under more mild conditions by first deprotonating the enaminone to form the anion followed by exposure to cadmium(II) salts at 60 degrees C to 90 degrees C. Alternatively the enaminones may be reacted with organocadmium reagents such as dibutylcadmium to effect the deprotonation and cyclization directly at room temperature. Synthetic applications of these novel cadmium-mediated cyclizations are presented and mechanistic considerations discussed.

  DOI：

  10.1021/jo00121a048
• 作为产物：
  描述：

  Methyl 2,4-dioxo-1-propylpyrrolidine-3-carboxylate 生成 1-丙基吡咯烷-2,4-二酮
  参考文献：
  名称：

  CAMPBELL, J. B. ,, JR.

  摘要：

  DOI：

文献信息

• Certain 1H-pyrrold[3,4-b]quinolin-1-one-9-amino-2,3-dihydro derivatives
  申请人：ICI Americas Inc.

  公开号：US04975435A1

  公开（公告）日：1990-12-04

  The present invention comprises certain quinoline lactams of formula I; pharmaceutically acceptable salts of the compounds of formula I; pharmaceutical compositions containing a compound of formula I, or a pharmaceutically acceptable salt thereof, for use in the treatment of anxiety; and processes for the manufacture of the compounds of formula I, as well as intermediates for use in such manufacture.

  本发明涵盖了某些式I的喹啉内酰胺；式I化合物的药学上可接受的盐；含有式I化合物或其药学上可接受的盐的药物组合物，用于治疗焦虑；以及用于制造式I化合物的工艺，以及用于此类制造的中间体。
• Synthesis of 5-Substituted Aminopyrrolo[3,4-b]quinolinones by a Diorganozinc-Mediated Tandem Alkylation/Cyclization
  作者：James B. Campbell、Judy W. Firor

  DOI：10.1080/00397911.2010.542537

  日期：2012.6

  with N-(oxopyrrolin-4-yl)-3-chloromethylbenzonitriles provides 5-substituted aminopyrrolo[3,4-b]quinolines by an overall single-pot, tandem alkylation/cyclization sequence. Mechanistic considerations suggest an in situ–generated ortho-quinone methide imine (aza-ortho-xylylene) as a reactive intermediate, which may trap an alkyl group from the diorganozinc reagent by a conjugate addition. GRAPHICAL

  摘要 二有机锌试剂与 N-(oxopyrrolin-4-yl)-3-chloromethylbenzonitriles 的反应通过整体单锅串联烷基化/环化序列提供 5-取代的氨基吡咯并 [3,4-b] 喹啉。机理考虑表明，原位生成的邻醌甲基亚胺（氮杂邻二甲苯）作为反应中间体，可以通过共轭加成从二有机锌试剂中捕获烷基。图形概要
• Tetrahydropyridoquinolone derivatives useful as anxiolytic agents
  申请人：ICI Americas Inc.

  公开号：US05118688A1

  公开（公告）日：1992-06-02

  The present invention comprises certain quinoline lactams of formula I; pharmaceutically acceptable salts of the compounds of formula I; pharmaceutical compositions containing a compound of formula I, or a pharmaceutically acceptable salt thereof, for use in the treatment of anxiety; and processes for the manufacture of the compounds of formula I, as well as intermediates for use in such manufacture.

  本发明包括公式I的某些喹啉内酰胺；公式I化合物的药学上可接受的盐；含有公式I化合物或其药学上可接受的盐的制剂，用于治疗焦虑症；以及制造公式I化合物的工艺，以及用于此类制造的中间体。
• Pyrazolopyridine compounds
  申请人：ICI AMERICAS INC.

  公开号：EP0094175A1

  公开（公告）日：1983-11-16

  Compounds of the formula (I): wherein D is oxygen or NR6, R1, R3, R4, R6, R7 and R8 have defined values, and n is 1 or 2, and pharmaceutically-acceptable acid-addition salts thereof, processes for their preparation, pharmaceutical compositions, and intermediates for preparing said compounds of the formula (I). The compounds of the formula (I) are central nervous system depressants, for example, anxiolytic agents.

  式(I)化合物： 其中 D 是氧或 NR6，R1、R3、R4、R6、R7 和 R8 具有定义值，n 是 1 或 2，以及其药学上可接受的酸加成盐、其制备工艺、药物组合物和制备所述式 (I) 化合物的中间体。式（I）化合物是中枢神经系统抑制剂，例如抗焦虑剂。
• ——
  作者：

  DOI：——

  日期：——